Press Releases Silence Therapeutics plc

Equities

SLN

US82686Q1013

Real-time Estimate Cboe BZX Other stock markets 15:28:09 2024-06-27 EDT			5-day change	1st Jan Change
19.24 ^USD	+5.05%		+2.51%	+11.54%

08:19pm	Sector Update: Health Care Stocks Decline in Afternoon Trading	MT
06:12pm	European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients	07:31am	BU
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration	06-24	BU
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)	06-20	BU
Silence Therapeutics to Present at Jefferies Global Healthcare Conference	05-30	BU
Silence Therapeutics : Condensed consolidated income statement (unaudited) - Form 6-K	05-16	PU
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress	05-16	BU
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference	04-30	BU
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors	04-29	BU
Silence Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	04-15	PU
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	04-08	BU
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	03-13	BU
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)	03-13	BU
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024	02-28	BU
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	02-26	AQ
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	02-23	BU
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement	02-05	BU
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01-31	BU
Gubra concludes the research agreement with UK Biotech	01-26	AQ
Silence Therapeutics : Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief Scientific Officer - Form 6-K	12-01	PU
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments	12-01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Silence Therapeutics plc

Equities

SLN

US82686Q1013

Press Releases

Filters